Tipranavir: Difference between revisions
imported>David E. Volk (New page: {{subpages}} right|thumb|250px|{{#ifexist:Template:Tipranavir structure.jpg/credit|{{Tipranavir structure.jpg/credit}}<br/>|}}Tipranavir '''Tipranavir'...) |
mNo edit summary |
||
| (5 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
{{Chem infobox | |||
|align=right | |||
|image=[[Image:Tipranavir structure.jpg|center|thumb|250px]]]] | |||
|width=250px | |||
|molname=tipranavir | |||
|synonyms= Aptivus® | |||
|molformula= C<sub>31</sub>H<sub>33</sub>F<sub>3</sub>N<sub>2</sub>O<sub>5</sub>S | |||
|molmass= 602.6643 | |||
|uses=HIV | |||
|properties=protease inhibitor | |||
|hazards=see drug interactions | |||
|iupac= see chemistry section | |||
|casnumber= 174484-41-4 | |||
}} | |||
'''Tipranavir''' ('''TPV'''), sold under the brand name '''Aptivus®''', is a nonpeptidic [[protease inhibitor]] drug used to treat [[HIV]]/[[AIDS]] in combination with [[ritonavir]]. It is used for patients with extensive previous treatment of those infected with HIV strains that have multiple protease inhibitor resistance. Tipranavir blocks the function of protease enzymes sothat the Gag and Gag-Pol polyprotein cannot be cleaved into individual active proteins, thus blocking the formation of infectious mature viral particles. Such inhibitors all almost always used in a combination therapy with other anti-HIV drugs. | |||
== Chemistry == | |||
Its IUPAC chemical name is Name N-[3-[(1R)-1-[(6R)-2-hydroxy-4-oxo-6-(2-phenylethyl)-6-propyl-5H-pyran-3-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide and its chemical formula is C<sub>31</sub>H<sub>33</sub>F<sub>3</sub>N<sub>2</sub>O<sub>5</sub>S. | Its IUPAC chemical name is Name N-[3-[(1R)-1-[(6R)-2-hydroxy-4-oxo-6-(2-phenylethyl)-6-propyl-5H-pyran-3-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide and its chemical formula is C<sub>31</sub>H<sub>33</sub>F<sub>3</sub>N<sub>2</sub>O<sub>5</sub>S. | ||
== External Links == | == External Links == | ||
{{CZMed}} | |||
[[Category:Suggestion Bot Tag]] | |||
Latest revision as of 06:01, 29 October 2024
| |||||||
| tipranavir | |||||||
| |||||||
| Uses: | HIV | ||||||
| Properties: | protease inhibitor | ||||||
| Hazards: | see drug interactions | ||||||
| |||||||
Tipranavir (TPV), sold under the brand name Aptivus®, is a nonpeptidic protease inhibitor drug used to treat HIV/AIDS in combination with ritonavir. It is used for patients with extensive previous treatment of those infected with HIV strains that have multiple protease inhibitor resistance. Tipranavir blocks the function of protease enzymes sothat the Gag and Gag-Pol polyprotein cannot be cleaved into individual active proteins, thus blocking the formation of infectious mature viral particles. Such inhibitors all almost always used in a combination therapy with other anti-HIV drugs.
Chemistry
Its IUPAC chemical name is Name N-[3-[(1R)-1-[(6R)-2-hydroxy-4-oxo-6-(2-phenylethyl)-6-propyl-5H-pyran-3-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide and its chemical formula is C31H33F3N2O5S.
External Links
The most up-to-date information about Tipranavir and other drugs can be found at the following sites.
- Tipranavir - FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).
- Tipranavir - Drug information for consumers from MedlinePlus (U.S. National Library of Medicine).
- Tipranavir - Detailed information from DrugBank.